New drug candidate offers hope for Treatment-Resistant depression
NCT ID NCT03870776
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested a daily oral drug called MAP4343 in 126 adults whose depression did not improve with standard antidepressants. Participants took either MAP4343 or a placebo for 6 weeks. The main goal was to see if the drug reduced depression symptoms more than placebo, measured by a standard rating scale. The study is complete, and results will show whether MAP4343 is safe and effective for this hard-to-treat group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MAP4343 (an oral drug)
What this could lead to
If it works, this could offer a new option for people with depression that doesn't respond to standard antidepressants.
What could go wrong
This is an early phase 2 trial with only 126 people, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP Hôpital La Pitié Salpétrière - Prinicipal investigator center
Paris, 75013, France
-
CHD Vendée
La Roche-sur-Yon, 85000, France
-
CHRU Tours
Tours, 37000, France
-
CHU Angers
Angers, 49900, France
-
CHU Besançon
Besançon, 25000, France
-
CHU Henri Laborit
Poitiers, 86000, France
-
CHU Nantes
Nantes, 44000, France
-
Cabinet Médical Ambroise Paré
Élancourt, 78990, France
-
Hôpital Fontan 1
Lille, 59000, France
-
Hôpital Ste Anne
Paris, 75014, France